MedTrace Logo

Typhoid Conjugate Vaccine Introduction in Navi Mumbai, India

NCT03554213 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 17292

Last updated 2021-10-04

No results posted yet for this study

Summary

The purpose of this study is to evaluate the impact of a government-led typhoid conjugate vaccine introduction program on typhoid disease burden in Navi Mumbai, India.

Conditions

  • Enteric Fever
  • Typhoid Fever
  • Salmonella Typhi Infection

Interventions

BIOLOGICAL

Typhoid Conjugate Vaccine

Typbar TCV Vi-TT (Vi capsular polysaccharide conjugated with tetanus toxoid protein) manufactured by Bharat Biotech International Limited

Sponsors & Collaborators

Principal Investigators

  • Stephen Luby, MD · Stanford University

  • Kashmira Date, MD MPH · Centers for Disease Control and Prevention

  • Shanta Dutta, MD PhD · National Institute of Cholera and Enteric Diseases (NICED)

  • Pankaj Bhatnagar, MD · World Health Organization (WHO) - India

Eligibility

Min Age
6 Months
Max Age
16 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-07-02
Primary Completion
2021-03-31
Completion
2021-03-31

Countries

  • India

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03554213 on ClinicalTrials.gov